EFFICACY, SAFETY, AND TOLERABILITY OF AFQ056 FOR THE TREATMENT OF CHOREA IN PATIENTS WITH HUNTINGTON'S DISEASE

被引：0
|
作者：
Reilmann, R. [1 ,2 ]
Rouzade-Dominguez, M. [3 ]
Saft, C. [4 ]
Suessmuth, S. D. [5 ]
Priller, J. [6 ]
Rosser, A. [7 ,8 ]
Rickards, H. [9 ]
Schoels, L. [10 ]
Pezous, N. [11 ]
Gasparini, F. [12 ]
Landwehrmeyer, G. B. [5 ]
Johns, D. [13 ]
Gomez-Mancilla, B. [12 ]
机构：
[1] George Huntington Inst, D-48149 Munster, Germany
[2] Univ Munster, Dept Neurol, D-48149 Munster, Germany
[3] Novartis Pharma AG, Clin Sci & Innovat, CH-4056 Basel, Switzerland
[4] Ruhr Univ Bochum, Neurol Klin, D-44791 Bochum, Germany
[5] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany
[6] Charite, Dept Neuropsychiat, D-10117 Berlin, Germany
[7] Cardiff Univ, Sch Med, Neurosci & Mental Hlth Res Inst, Cardiff CF10 3AX, S Glam, Wales
[8] Cardiff Univ, Sch Biosci, Neurosci & Mental Hlth Res Inst, Cardiff CF10 3AX, S Glam, Wales
[9] Barberry, Dept Neuropsychiat, Birmingham B15 2FG, W Midlands, England
[10] Inst Clin Brain Res, Ctr Neurol & Hertie, Clin Neurogenet Unit, D-72076 Tubingen, Germany
[11] Novartis Pharma AG, IIS Translat Sci Early Dev Stat Res, CH-4002 Basel, Switzerland
[12] Novartis Pharma AG, Novartis Inst Biomed Res, CH-4056 Basel, Switzerland
[13] Novartis Inst Biomed Res Inc, Neurosci Translat Med, Cambridge, MA 02139 USA
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2014年 / 85卷
关键词：
D O I：
10.1136/jnnp-2014-309032.295
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
N03
引用
收藏
页码：A102 / A103
页数：3
相关论文
共 50 条
  • [21] Safety and tolerability of lamotrigine in Huntington's disease
    Higgins, DS
    Illouz, K
    Subramanian, P
    MOVEMENT DISORDERS, 2002, 17 : S324 - S324
  • [22] Minocycline safety and tolerability in Huntington's disease
    Cudkowicz, M
    MOVEMENT DISORDERS, 2003, 18 (09) : 1084 - 1085
  • [23] Treatment of chorea in Huntington disease
    Darwin, K.
    Nichols, P.
    Brocht, A.
    Dorsey, E. R.
    Beck, C.
    Biglan, K.
    Shoulson, Ira
    NEUROTHERAPEUTICS, 2013, 10 (01) : 173 - 173
  • [24] Treatment of chorea in Huntington's disease with ropinirole and pramipexole
    Gunzler, S. A.
    Buczek, M.
    MOVEMENT DISORDERS, 2009, 24 : S165 - S165
  • [25] Tetrabenazine treatment for Huntington's disease - Associated chorea
    Ondo, WG
    Tintner, R
    Thomas, M
    Jankovic, J
    CLINICAL NEUROPHARMACOLOGY, 2002, 25 (06) : 300 - 302
  • [26] deutetrabenazine for the treatment of chorea associated with Huntington's disease
    Gupta, Harshit
    Perkins, Wil
    Stark, Cain
    Kikkeri, Sathya
    Kakazu, Juyeon
    Kaye, Adam
    Kaye, Alan
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (05): : 1 - 9
  • [27] Pridopidine in treatment of Huntington's disease: beyond chorea?
    Feigin, Andrew
    LANCET NEUROLOGY, 2011, 10 (12): : 1036 - 1037
  • [28] Valbenazine for the treatment of chorea associated with Huntington's disease
    Patino, Jorge
    Furr Stimming, Erin
    Testa, Claudia M.
    Mehanna, Raja
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (02) : 127 - 132
  • [29] AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study
    Stocchi, Fabrizio
    Rascol, Olivier
    Destee, Alain
    Hattori, Nobutaka
    Hauser, Robert A.
    Lang, Anthony E.
    Poewe, Werner
    Stacy, Mark
    Tolosa, Eduardo
    Gao, Haitao
    Nagel, Jennifer
    Merschhemke, Martin
    Graf, Ana
    Kenney, Christopher
    Trenkwalder, Claudia
    MOVEMENT DISORDERS, 2013, 28 (13) : 1838 - 1846
  • [30] mGluR5 antagonist AFQ056/Mavoglurant in Fragile X Syndrome: baseline disease severity data in adults and adolescents
    Matthisson, M.
    Angelov, A.
    Jaecklin, T.
    Koumaras, B.
    Collober, C.
    Hossain, F. N.
    Lustig, J.
    Lee, J.
    Graf, A.
    von Raison, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S436 - S437
12345